Recent changes

Jump to navigation Jump to search

Track the most recent changes to the wiki on this page.

Recent changes options Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Show bots | Hide minor edits
Show new changes starting from 12:25, 9 May 2024
   
 
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

9 May 2024

N    10:45  FUTIBATINIB‎‎ 2 changes history +1,225 [Hafiza Amna Qadeer‎ (2×)]
     
10:45 (cur | prev) −12 Hafiza Amna Qadeer talk contribs
N    
10:37 (cur | prev) +1,237 Hafiza Amna Qadeer talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...")
N    04:57  Sotagliflozin diffhist +418 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}")

8 May 2024

     21:38  Template:KDRG diffhist +174 Kosar Doraghi talk contribs
N    21:38  EXXUA‎‎ 2 changes history +11,572 [Kosar Doraghi‎ (2×)]
     
21:38 (cur | prev) +11 Kosar Doraghi talk contribs
N    
21:32 (cur | prev) +11,561 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...")
     21:27  (Upload log) [Edzelco‎; Kosar Doraghi‎ (3×); Imam Ali Shah‎ (7×)]
     
21:27 Kosar Doraghi talk contribs uploaded File:IMG 1195.jpeg
     
21:26 Kosar Doraghi talk contribs uploaded File:IMG 1196.jpeg
     
21:19 Kosar Doraghi talk contribs uploaded File:IMG 1194.jpeg
     
17:11 Imam Ali Shah talk contribs uploaded File:Screenshot (245).jpg
     
17:02 Imam Ali Shah talk contribs uploaded File:RCR logo.png
     
16:30 Imam Ali Shah talk contribs uploaded a new version of File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg(Pre-contrast CT scan of the abdomen and pelvis depicts an irregular nodular margin of the liver (green arrowhead), hypertrophy of the caudate lobe (orange arrow), and the presence of ascites (red arrow).)
     
16:21 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
     
16:19 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
     
16:18 Imam Ali Shah talk contribs uploaded File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
     
16:17 Imam Ali Shah talk contribs uploaded File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
     
01:53 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png
     17:11  Cryptogenic cirrhosis‎‎ 6 changes history +3,131 [Imam Ali Shah‎ (6×)]
     
17:11 (cur | prev) +8 Imam Ali Shah talk contribs Tag: Visual edit
     
17:03 (cur | prev) +419 Imam Ali Shah talk contribs (Added CT scan images) Tag: Visual edit
     
16:45 (cur | prev) +1,626 Imam Ali Shah talk contribs (Added CT scan images) Tag: Visual edit
     
16:34 (cur | prev) +269 Imam Ali Shah talk contribs Tag: Visual edit
     
16:26 (cur | prev) +476 Imam Ali Shah talk contribs Tag: Visual edit
     
16:21 (cur | prev) +333 Imam Ali Shah talk contribs Tag: Visual edit
     16:03  User:Imam Ali Shah diffhist −61 Imam Ali Shah talk contribs Tag: Visual edit
N    14:44  Template:VSRN diffhist +81 Rithish Nimmagadda talk contribs (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]")
N    14:30  FRUZAQLA‎‎ 3 changes history +9,129 [Rithish Nimmagadda‎ (3×)]
     
14:30 (cur | prev) +2 Rithish Nimmagadda talk contribs Tag: Visual edit
     
14:25 (cur | prev) +35 Rithish Nimmagadda talk contribs
N    
14:10 (cur | prev) +9,092 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...")
N    14:21  User:Rithish Nimmagadda‎‎ 3 changes history +362 [Rithish Nimmagadda‎ (3×)]
     
14:21 (cur | prev) −9 Rithish Nimmagadda talk contribs (→‎Your Name)
     
14:21 (cur | prev) +9 Rithish Nimmagadda talk contribs (→‎Your Name)
N    
14:20 (cur | prev) +362 Rithish Nimmagadda talk contribs (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India")
N    13:32  Fruzaqla diffhist +49 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}")
     04:13  Zuranolone‎‎ 2 changes history +5,755 [Alen Antony‎ (2×)]
     
04:13 (cur | prev) +2,528 Alen Antony talk contribs
     
03:48 (cur | prev) +3,227 Alen Antony talk contribs
     01:58  User:Edzelco diffhist +22 Edzelco talk contribs (→‎Pages Authored/Co-authored/Collaborated)
     01:55  Toripalimab-tpzi diffhist +45,965 Edzelco talk contribs

7 May 2024

N    20:18  Zuranolone‎‎ 2 changes history +1,853 [Alen Antony‎ (2×)]
     
20:18 (cur | prev) +1,017 Alen Antony talk contribs
N    
17:27 (cur | prev) +836 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...")
     04:14  User:Archana.vajjala‎‎ 5 changes history +4 [Archana.vajjala‎ (5×)]
     
04:14 (cur | prev) −25 Archana.vajjala talk contribs (→‎Interests) Tag: Visual edit
     
04:09 (cur | prev) −40 Archana.vajjala talk contribs (→‎Interests) Tag: Visual edit
     
03:59 (cur | prev) +26 Archana.vajjala talk contribs (→‎Interests) Tag: Visual edit
     
03:56 (cur | prev) +3 Archana.vajjala talk contribs (→‎Interests) Tag: Visual edit
     
03:56 (cur | prev) +40 Archana.vajjala talk contribs (→‎Interests) Tag: Visual edit
     03:37  Perfluorhexyloctane diffhist +904 Alen Antony talk contribs

6 May 2024

     13:14  User:Archana.vajjala‎‎ 4 changes history +9 [Archana.vajjala‎ (4×)]
     
13:14 (cur | prev) −24 Archana.vajjala talk contribs (→‎Licensure & Certification) Tag: Visual edit
     
13:10 (cur | prev) +8 Archana.vajjala talk contribs (→‎Licensure & Certification) Tag: Visual edit
     
13:10 (cur | prev) 0 Archana.vajjala talk contribs (→‎Interests) Tag: Visual edit
     
13:09 (cur | prev) +25 Archana.vajjala talk contribs (→‎Licensure & Certification) Tag: Visual edit